Contains Nonbinding Recommendations

Guidance on Efavirenz

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Efavirenz
Form/Route: Tablets/Oral
Recommended studies: 1 study

Type of study: Fasting
Design: Single-dose, two-way crossover in-vivo
Strength: 600 mg
Subjects: Normal healthy males and females, general population.

Additional Comments:

Analytes to measure: Efavirenz in plasma
Bioequivalence based on (90% CI): Efavirenz
Waiver request of in-vivo testing: Not Applicable
Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Finalized May 2008